A mighty oak in the rapidly expanding field of checkpoint inhibition for NSCLC
In the Lancet issue of last December Rittmeyer and colleagues reported the primary efficacy analysis of another landmark immunotherapy study (1): the randomized phase 3 OAK trial comparing atezolizumab (n=425), an anti-programmed death-ligand 1 (PD-L1) monoclonal antibody, with docetaxel (n=425) for...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) Editorial |
| Language: | English |
| Published: |
Feb 09, 2017
|
| In: |
Journal of thoracic disease
Year: 2017, Volume: 9, Issue: 3, Pages: E292-E294 |
| ISSN: | 2077-6624 |
| DOI: | 10.21037/jtd.2017.02.86 |
| Online Access: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.21037/jtd.2017.02.86 Verlag, kostenfrei, Volltext: http://jtd.amegroups.com/article/view/12412 
|
| Author Notes: | Petros Christopoulos, Michael Thomas |
| Summary: | In the Lancet issue of last December Rittmeyer and colleagues reported the primary efficacy analysis of another landmark immunotherapy study (1): the randomized phase 3 OAK trial comparing atezolizumab (n=425), an anti-programmed death-ligand 1 (PD-L1) monoclonal antibody, with docetaxel (n=425) for patients with squamous or adenocarcinomatous non-small cell lung cancer (NSCLC) progressing after one or more platinum-based combination regimens. |
|---|---|
| Item Description: | Gesehen am 20.07.2018 |
| Physical Description: | Online Resource |
| ISSN: | 2077-6624 |
| DOI: | 10.21037/jtd.2017.02.86 |